Novavax Inc., of Rockville, Md., said it started enrollment in a Phase II trial of its quadrivalent seasonal influenza virus-like particle vaccine candidate. The study, being conducted under the firm's contract with the Department of Health and Human Services' Office of Biomedical Advanced Research and Development Authority, is designed to evaluate the immunogenicity and safety of three dose levels of the vaccine in healthy adults, ages 18 to 64.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST